AOD-9604 purity and testing: what buyers actually need to check

Last updated 2026-07-25

What does "purity" even mean for a peptide like AOD-9604?

Purity means two separate things and sellers often blur them together. First: is the peptide in the vial actually AOD-9604, the 15-amino-acid fragment of human growth hormone (hGH 176-191), and not something else entirely? Second: how much of what's in there is that peptide, versus leftover solvents, uncoupled amino acids, or synthesis byproducts? A certificate of analysis (COA) from a real lab usually reports both. High-performance liquid chromatography (HPLC) gives you a purity percentage by measuring how much of the sample elutes as a single clean peak. Mass spectrometry confirms molecular weight and identity, so you know you're not looking at a fragment that happens to have similar solubility but the wrong sequence. Here's the catch nobody selling this stuff wants to say out loud: there is no FDA reference standard for AOD-9604 to test against, because it isn't an approved drug. Approved drugs listed in the Drugs@FDA database have official reference standards and monograph specs ^[1]. AOD-9604 has none. So a 98% purity number is only as good as the lab that produced it and the reference material they used to calibrate.

Is AOD-9604 FDA-approved, and does that affect testing standards?

No. AOD-9604 has never been approved by the FDA for any indication. You can check this yourself in the Drugs@FDA database, which lists every approved drug product with its application number, sponsor, and approval history ^[1]. AOD-9604 doesn't appear there because it was never approved. That matters for testing because FDA approval comes with mandated purity specs, stability data, and manufacturing controls under Good Manufacturing Practice. Without approval, there's no legal floor for what counts as acceptable purity. A supplier can call something "research grade" or "98% pure" with zero external audit unless they voluntarily pay for third-party testing and post the results. AOD-9604 is also not on either FDA bulk drug substance list that governs compounding. It's not on the 503A bulks list for compounding pharmacies ^[2], and it's not on the 503B list for outsourcing facilities that produce sterile compounded drugs at scale ^[3]. Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) requires the substance to appear on FDA's approved bulks list or meet other narrow criteria ^[4]. AOD-9604 doesn't clear that bar. This is a big part of why sourcing is messy: legitimate compounding pharmacies have a real regulatory reason to stay away from it, which pushes supply toward research-chemical vendors with far less oversight.

What should a real AOD-9604 certificate of analysis include?

A COA worth trusting names the testing lab, the batch or lot number, the test date, and the specific methods used (typically HPLC for purity, mass spec for identity, and sometimes an endotoxin or sterility test if the product claims to be injectable-grade). It should report a numeric purity percentage, more than the word "pure." Red flags: a COA with no lab name, no lot number, or a purity figure that's suspiciously round (100.0% doesn't happen in real chromatography). Also watch for a COA that doesn't match the lot number printed on your vial. A generic PDF that a supplier reuses across every batch tells you nothing about the vial in your hand. Even a clean COA has limits. It tells you what was in that tested sample, not what's in every vial from that batch, and it says nothing about sterility, endotoxin levels, or whether the vial was stored and shipped at the right temperature. None of this substitutes for regulatory oversight, because there isn't any for this compound.

Does AOD-9604 show up on WADA or anti-doping drug tests?

There's real research on this specific question, separate from the general purity issue. A 2013 study in Drug Testing and Analysis tested whether AOD-9604 interferes with the World Anti-Doping Agency's hGH isoform immunoassay, the standard test labs use to detect growth hormone doping. The finding: AOD-9604 does not influence the WADA hGH isoform immunoassay ^[5]. That means the fragment doesn't get flagged by the assay built to catch synthetic hGH itself. That doesn't mean AOD-9604 is undetectable or legal in sport. Separate detection science has moved on to catch smaller peptides directly. A 2014 review in Expert Review of Proteomics covers current and developing methods for detecting peptidic drugs and drug candidates, including fragments like AOD-9604, in doping control ^[6]. Another 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covers analytical approaches specifically built for emerging and non-approved therapeutics in doping controls ^[7]. And a 2016 method in the Journal of Separation Science describes a direct urine injection approach using liquid chromatography and ion mobility mass spectrometry built to screen peptides under 2 kDa, a size range that includes fragments like this one ^[8]. AOD-9604 is on WADA's prohibited list as a growth hormone releasing peptide/fragment. If you're a tested athlete, the honest answer is: don't use it, full stop, regardless of what purity testing shows.

Does purity testing prove AOD-9604 works for fat loss?

No, and this is the part that gets buried by sellers. Purity testing answers a chemistry question, not a physiology question. A vial can be 99% pure AOD-9604 and still not move the needle on body fat, because the human trial data on that exact question isn't strong. AOD-9604 was developed specifically because researchers wanted the fat-metabolizing region of hGH (the C-terminal fragment, residues 176-191) without the growth-promoting, insulin-resistance-inducing effects of full hGH. A 2004 paper in Current Opinion in Investigational Drugs lays out this metabolic rationale and early findings ^[9]. It's a reasonable idea on paper. The lipolytic fragment concept isn't nonsense biology. But reasonable biology and confirmed clinical results are different things. A 2006 review of obesity drugs in clinical development covers where AOD-9604 sat in the pipeline at that time, alongside other candidates being tested for weight loss ^[10]. The compound went through Phase II human obesity trials. The weight-loss results did not separate convincingly from placebo. That's the central, unavoidable fact for anyone evaluating this peptide for fat loss, and no purity certificate changes it. You can read more on the underlying evidence for AOD-9604 and how the trial data actually reads.

How do vendor purity claims compare to what's actually been verified in trials?

The table above is the honest comparison. A lot of buyer research time goes into scrutinizing COAs when the bigger gap is between "chemically present" and "clinically effective." Both matter, but they answer different questions, and a slick COA can make people stop asking the second one.

How does AOD-9604 compare to peptides with stronger human evidence?

Tesamorelin is the clearest contrast. It's FDA-approved (for HIV-associated lipodystrophy), meaning it went through full Phase III trials with published, peer-reviewed efficacy data and has an official reference standard in Drugs@FDA ^[1]. AOD-9604 has neither. If you're weighing the two, the comparison isn't close on regulatory footing or evidence quality, even though they get marketed to overlapping audiences. See the detailed AOD-9604 vs tesamorelin comparison for dosing, mechanism, and trial differences side by side. More broadly, a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics, including applications, challenges, and open questions for peptide therapies as a category ^[11]. A separate 2026 paper in Sports Medicine reviews safety and efficacy data for both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[12]. Both papers frame the same tension that applies here: some peptides in this broad category have real trial support, and some are riding on mechanism plausibility alone. AOD-9604 sits closer to the second group based on its published obesity trial outcomes.

What did the actual AOD-9604 clinical trials find?

The trial pipeline is documented in a series of "Gateways to Clinical Trials" round-ups published in Methods and Findings in Experimental and Clinical Pharmacology, which tracked AOD-9604 as it moved through development in 2003 and 2005 ^[13][14][15]. These aren't full trial reports; they're pharmacology-journal digests that log which compounds were in which trial phase and what was publicly known at the time. What's consistent across the record: AOD-9604 reached Phase II testing for obesity, and the topline weight-loss signal against placebo was not strong enough to support approval or to convince the compound's own developer to push it through Phase III as an obesity drug. The 2004 metabolic-mechanism paper ^[9] and the 2006 obesity-drug-pipeline review ^[10] both come from the same era and describe the same basic picture: a plausible mechanism that didn't translate into a clean clinical win. If someone tells you AOD-9604 "passed clinical trials," ask which trial and what the actual placebo-adjusted result was. The honest answer, based on the published record, is that it reached testing but didn't clear the bar that separates a promising mechanism from a proven drug.

What should I actually check before buying AOD-9604?

Ask for a current COA tied to the specific lot number on your vial, not a stock PDF. Confirm the testing lab is named and, ideally, independently searchable. Check that the purity percentage is specific (94.2%, not "pure") and that mass spec identity confirmation is included alongside HPLC purity. Then separate that from the bigger question: are you buying this because you've weighed the trial evidence and decided the mechanism is worth trying anyway, or because marketing copy implied it's a proven fat-loss drug? The second reason isn't a good one, given what the Phase II obesity data actually showed ^[9][10][13]. If you do go ahead, buying through a provider-reviewed pathway matters more than any single COA. AOD-9604 Co reviews sourcing routes and points toward the pharmacy partner that actually fulfills orders, rather than compounding or manufacturing anything itself. That's a meaningfully different check than trusting a random COA screenshot from a vendor's product page. For a breakdown of vetted options, see best place to buy AOD-9604 and the general AOD-9604 for sale sourcing guide.

What about dosing and handling once you have a tested product?

Purity testing and correct handling are two different safety layers, and both matter once a vial is in your hands. Reconstitution errors (wrong diluent volume, non-sterile technique, wrong storage temperature) can degrade even a genuinely pure peptide fast, turning a good COA into a moot point within days. If you're at this stage, walk through how to reconstitute AOD-9604 step by step before opening a vial, and check when to take AOD-9604 peptide for timing questions that come up constantly and have nothing to do with purity at all. None of this changes the core evidence picture. Good handling of a pure product still isn't the same as good clinical proof that the product changes body fat in humans beyond placebo.

Frequently asked questions

Is there an FDA-approved purity standard for AOD-9604?

No. AOD-9604 has never been approved by the FDA, so it has no official reference standard or monograph spec. You can confirm this by searching the Drugs@FDA database directly; AOD-9604 doesn't appear because it was never approved for any indication.

What lab tests confirm AOD-9604 purity?

HPLC (high-performance liquid chromatography) measures purity percentage by isolating a clean chromatographic peak. Mass spectrometry confirms molecular identity, verifying the sample matches the expected AOD-9604 sequence and weight. A trustworthy certificate of analysis includes both, plus the lab name, lot number, and test date.

Can AOD-9604 be legally compounded by a pharmacy?

It's not on either FDA bulk drug substance list used for compounding. It's absent from the 503A bulks list for compounding pharmacies and the 503B list for outsourcing facilities, which is why legitimate compounding pharmacies generally avoid it and supply skews toward less-regulated research-chemical vendors.

Does AOD-9604 show up on a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard test for growth hormone doping. But newer mass-spec-based methods built specifically to catch small peptides in urine can potentially detect it, and it remains on WADA's prohibited list regardless of assay detectability.

Did AOD-9604 pass human clinical trials for weight loss?

It reached Phase II obesity trials, documented in clinical trial round-ups from 2003 and 2005. The weight-loss results did not separate convincingly from placebo. A 98%+ purity certificate doesn't change that outcome; the trial gap is a clinical evidence problem, not a manufacturing one.

How is AOD-9604 supposed to work for fat loss?

It's a 15-amino-acid fragment of human growth hormone (residues 176-191), designed to isolate the fat-metabolizing region of hGH without the growth-promoting effects. The mechanism is biologically plausible and described in a 2004 paper in Current Opinion in Investigational Drugs, but plausible mechanism and confirmed clinical benefit are separate things.

Is AOD-9604 the same thing as HGH?

No. It's a small fragment of the HGH molecule, not the full hormone. That's the entire design rationale: isolate the piece thought to drive fat metabolism while leaving out the parts of hGH linked to growth effects and insulin resistance. It's not expected to raise IGF-1 the way full hGH does.

What red flags suggest a fake or low-purity AOD-9604 product?

A COA with no named lab, no lot number, or one that doesn't match your vial's lot number. Round purity numbers like 100.0% are also a warning sign, since real chromatography rarely produces one. Reused generic PDFs across different batches tell you nothing about the specific vial you bought.

Is AOD-9604 better tested or better researched than tesamorelin?

No. Tesamorelin is FDA-approved with full Phase III trial data and an official reference standard listed in Drugs@FDA. AOD-9604 has neither. If regulatory backing and trial strength matter to your decision, tesamorelin has a materially stronger record.

Does third-party purity testing make AOD-9604 safe to use?

It reduces one risk (contamination or wrong-compound risk) but says nothing about whether the peptide is effective or about longer-term safety in humans, since it was never approved and large-scale safety trials were never completed for obesity use.

Why isn't AOD-9604 sold through normal pharmacies?

Because it's not FDA-approved and isn't on either FDA bulk drug substance list that permits pharmacy compounding under section 503A of the Food, Drug, and Cosmetic Act. That regulatory gap is exactly why sourcing runs through research-chemical channels rather than standard prescription pharmacy dispensing.

What should I actually verify before buying AOD-9604?

Get a lot-specific COA naming the lab, test date, and method (HPLC plus mass spec), confirm the purity percentage is specific rather than rounded, and separate that from the clinical question entirely. A clean COA tells you what's in the vial, not whether Phase II obesity trials support using it.

Sources

1. FDA, Drugs@FDA approved drug products database: AOD-9604 does not appear in the FDA-approved drug database because it has never been approved; tesamorelin, by contrast, is listed as approved.
2. eCFR, 21 CFR 216.23, the 503A Bulks List: AOD-9604 is not included on the FDA's 503A bulk drug substances list used by compounding pharmacies.
3. eCFR, 21 CFR 216.24, the 503B Bulks List: AOD-9604 is not included on the FDA's 503B bulk drug substances list used by outsourcing facilities.
4. Cornell Law/Legal Information Institute, 21 U.S.C. 353a (pharmacy compounding): Section 503A of the FD&C Act requires a bulk drug substance to be on FDA's approved list (or meet narrow exceptions) to be legally compounded.
5. PubMed PMID 24124033, Drug Testing and Analysis, 2013: AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping.
6. PubMed PMID 25382550, Expert Review of Proteomics, 2014: Reviews current and developing analytical methods for detecting peptidic drugs and drug candidates, including fragments like AOD-9604, in sports doping controls.
7. PubMed PMID 24906629, Journal of Pharmaceutical and Biomedical Analysis, 2014: Describes analytical approaches developed specifically to detect emerging therapeutics and non-approved drugs in human doping controls.
8. PubMed PMID 26578461, Journal of Separation Science, 2016: Describes a direct urine injection LC and ion mobility mass spectrometry method for screening peptides under 2 kDa.
9. PubMed PMID 15134286, Current Opinion in Investigational Drugs, 2004: Describes the metabolic/fat-mobilizing mechanism rationale for AOD-9604 as a fragment of human growth hormone.
10. PubMed PMID 16625817, Current Opinion in Investigational Drugs, 2006: Reviews obesity drugs in clinical development, including AOD-9604's position in the development pipeline at that time.
11. PubMed PMID 41490200, JAAOS Global Research & Reviews, 2026: Reviews therapeutic peptides in orthopaedics, covering applications, challenges, and future directions for the peptide therapy category.
12. PubMed PMID 41966639, Sports Medicine, 2026: Reviews safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance.
13. PubMed PMID 14685303, Methods and Findings in Experimental and Clinical Pharmacology, 2003: Tracks AOD-9604 in clinical trial development stages as part of a 2003 clinical trials gateway round-up.
14. PubMed PMID 14571286, Methods and Findings in Experimental and Clinical Pharmacology, 2003: Additional 2003 clinical trials gateway entry logging AOD-9604's development status.
15. PubMed PMID 15834452, Methods and Findings in Experimental and Clinical Pharmacology, 2005: 2005 clinical trials gateway round-up tracking AOD-9604's continued development status.